Top

Published in:

01-06-2007 | Original Paper

Deficiency of Invariant NK T Cells in Crohn's Disease and Ulcerative Colitis

Authors: Randall H. Grose, Fiona M. Thompson, Alan G. Baxter, Daniel G. Pellicci, Adrian G. Cummins

Published in: Digestive Diseases and Sciences | Issue 6/2007

Abstract

The aim of this study was to investigate whether immunoregulatory invariant NK T cells are deficient in Crohn's disease or ulcerative colitis. Blood was collected for flow cytometry from 106 Crohn's disease, 91 ulcerative colitis, and 155 control subjects. Invariant NK T cells were assessed by Vα24 and (α-galactosylceramide/CD1d tetramer markers. Intracellular cytokine was measured after in vitro anti-CD3 antibody stimulation. Vα24+ T cells were quantified in ileocolonic biopsies as mRNA by real-time PCR and by immunofluorescence. Circulating invariant NK T cells were 5.3% of the control levels in Crohn's (P < 0.001) and 7.9% of the control levels in ulcerative colitis (P < 0.001). Interleukin-4 production was impaired in Crohn's disease and ulcerative colitis. Intestinal Vα24 mRNA expression was 7% in Crohn's disease (P < 0.05) and 9% in ulcerative colitis (P < 0.05). Intestinal Vα24+ T cells were 23% in Crohn's disease but not reduced in ulcerative colitis. We conclude that invariant NK T cells are deficient in Crohn's disease and in ulcerative colitis.

Duchmann R, Kaiser I, Hermann E, Mayet W, Ewe K, Meyer Zum Büschenfelde K-H (1995) Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease. Clin Exp Immunol 102:448–455PubMedCrossRef

MacDonald TT (1995) Breakdown of tolerance to the intestinal bacterial flora in inflammatory bowel disease (IBD). Clin Exp Immunol 102:445–447PubMedCrossRef

Kraus TA, Toy L, Chan L, Childs J, Cheifetz A, Mayer L (2004) Failure to induce oral tolerance in Crohn's and ulcerative colitis patients: possible genetic risk. Ann NY Acad Sci 1029:225–238PubMedCrossRef

Kraus TA, Toy L, Chan L, Childs J, Mayer L (2004) Failure to induce oral tolerance to a soluble protein in patients with inflammatory bowel disease. Gastroenterology 126:1771–1778PubMedCrossRef

Lodes MJ, Cong Y, Elson CO, Mohamath R, Landers CJ, Targan SR, Fort M, Hershberg RM (2004) Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest 113:1296–1306PubMedCrossRef

MacDonald TT, DiSabatino A, Gordon JN (2005) Immunopathogenesis of Crohn's disease. JPEN 29:S118

Fuss IJ, Heller F, Boirivant M, Leon F, Yoshida M, Fichtner-Fiegl S, Yang Z, Exley M, Kitani A, Blumberg RS (2004) Non classical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest 113:1490–1497PubMedCrossRef

Heller F, Florian P, Bojarski C, Richter J, Christ M, Hillenbrand B, Mankertz J, Gitter AH, Burgel N, Fromm M, Zeitz M, Fuss I, Strober W, Schulzke JD (2005) Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 129:550–564PubMedCrossRef

Mayer L (2005) Editorial. A novel approach to the treatment of ulcerative colitis. Gastroenterology 128:1117–1119PubMedCrossRef

10.

Karttunnen R, Breese EJ, Walker-Smith JA, MacDonald TT (1994) Decreased mucosal interleukin-4 (IL-4) production in gut inflammation. J Clin Pathol 47:1015–1018PubMed

11.

West GA, Matsuura T, Levine AD, Klein JS, Fiocchi C (1996) Interleukin 4 in inflammatory bowel disease and mucosal reactivity. Gastroenterology 110:1683–1695PubMedCrossRef

12.

Joyce S, Woods AS, Yewdell JW, Bennink JR, De Silva AD, Boesteanu A, Balk SP, Cotter RJ, Brutkiewicz RR (1998) Natural ligand of mouse CD1d1: cellular glycosylphosphatidylinositol. Science 279:1541–1544PubMedCrossRef

13.

Godfrey DI, Hammond KJL, Poulton LD, Smyth MJ, Baxter AG (2000) NKT cells: facts, functions and fallacies. Immunol Today 21:573–583PubMedCrossRef

14.

Nieda M, Nicol A, Koezuka Y, Kikuchi A, Takahashi T, Nakamura H, Furukawa H, Yabe T, Ishikawa Y, Tadokoro K, Juji T (1999) Activation of human Valpha24NKT cells by alpha-glycosylceramide in a CD1d-restricted and Valpha24TCR-mediated manner. Hum Immunol 60:10–11PubMedCrossRef

15.

Matsuda JL, Naidenko OV, Gapin L, Nakayama T, Taniguchi M, Wang CR, Koezuka Y, Kronenberg M (2000) Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers. J Exp Med 192:741–754PubMedCrossRef

16.

van der Vliet HJ, von Blomberg BM, Nishi N, Reijm M, Voskuyl AE, van Bodegraven AA, Polman CH, Rustemeyer T, Lips P, van den Eertwegh AJ, Giaccone G, Scheper RJ, Pinedo HM (2001) Circulating VSp(alpha24+) Vbeta11+ NKT cell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage. Clin Immunol 100:144–148PubMedCrossRef

17.

Illes Z, Kondo T, Newcombe J, Oka N, Tabira T, Yamamura T (2000) Differential expression of NK T cell Valpha24JalphaQ invariant TCR chain in the lesions of multiple sclerosis and chronic inflammatory demyelinating polyneuropathy. J Immunol 164:4375–4381PubMed

18.

Harper JF (1994) Pertiz’ F test: BASIC programme of a robust multiple comparison test for statistical comparison for statistical analysis of all differences among group means. Comput Biol Med 14:437–445CrossRef

19.

Maeda T, Kelno H, Asahara H, Taniguchi M, Nishioka K, Sumida T (1999) Decreased TCR AV24αJ18 double-negative T cells in rheumatoid synovium. Rheumatology 38:186–188PubMedCrossRef

20.

Wilson SB, Kemi SC, Patton KT, Orban T, Jackson RA, Exley M, Porcelli S, Schatz DA, Atkinson MA, Balk SP, Strominger JL, Hafler DA (1998) Extreme Th1 bias of invariant Vα24JαQ T cells in type 1 diabetes. Nature 391:177–181PubMedCrossRef

21.

Sumida T, Sakamoto A, Murata H, Makino Y, Takahashi H, Yoshida S, Nishioka K, Iwamoto I, Tanguchi M (1995) Selective reduction of T cells bearing invariant V-alpha-24J alpha-Q antigen receptor in patients with systemic sclerosis. J Exp Med 182:1163–1168PubMedCrossRef

22.

Mendiratta SK, Martin WD, Hong S, Boesteanu A, Joyce S, Kaer LV (1997) CD1d1 mutant mice are deficient in natural T cells that promptly produce IL-4. Immunity 6:469–477PubMedCrossRef

23.

Zhang B, Yamamura T, Kondo T, Fujiwara M, Tabira T (1997) Regulation of experimental autoimmune encephalomyelitis by natural killer (NK) cells. J Exp Med 186:1677–1687PubMedCrossRef

24.

Trop S, Samsonov D, Gotsman I, Alper R, Diment J, Ilan Y (1999) Liver-associated lymphocytes expressing NK1.1 are essential for oral immune tolerance induction in a murine model. Hepatology 29:746–755PubMedCrossRef

25.

Saubermann LJ, Beck P, De Jong Y, Pitman RS, Ryan MS, Kim HS, Exley M, Snapper S, Balk SP, Hagen SJ, Kanauchi O, Motoki K, Sakai T, Terhorst C, Koezuka K, Podolsky DK, Blumberg RS (2000) Activation of natural killer T cells by α-galactosylceramide in the presence of CD1d provides protection against colitis in mice. Gastroenterology 119:119–128PubMedCrossRef

26.

Jordan MA, Fletcher J, Baxter AG (2004) Genetic control of NKT cell numbers. Immunol Cell Biol 82:276–284PubMedCrossRef

27.

Berzin SP, Uldrich AP, Pellicci DG, McNab F, Hayakawa Y, Smyth MJ, Godfrey DI (2004) Parallels and distinctions between T and NKT cell development in the thymus. Immunol Cell Biol 82:269–275CrossRef

28.

Godfrey DI, MacDonald R, Kronenberg M, Smyth MJ, van Kaer L (2004) NKT cells: What's in a name? Nat Rev Immunol 4:231–237PubMedCrossRef

29.

Vainer B, Nelson OH, Hendel J, Horn T, Kirman I (2000) Colonic expression and synthesis of interleukin 13 and interleukin 15 in inflammatory bowel disease. Cytokine 12:1531–1536PubMedCrossRef

30.

Kadivar K, Ruchelli ED, Markwitz JE, Defelice ML, Strogatz ML, Kanzaria MM, Reddy KP, Baldassano RN, von Allmen D, Brown KA (2004) Intestinal interleukin-13 in pediatric inflammatory bowel disease patients. Inflamm Bowel Dis 10:593–598PubMedCrossRef

31.

Inoue S, Matsumoto T, Lida M, Mizuno M, Kuroki F, Hoshika K, Shimizu M (1999) Characterization of cytokine expression in the rectal mucosa of ulcerative colitis: correlation with disease activity. Am J Gastroenterol 94:2441–2446PubMedCrossRef

32.

Yoshimoto T, Paul WE (1994) CD4pos NK1.1pos T cells promptly produce interleukin 4 in response to in vivo challenge with anti-CD3. J Exp Med 179:1285–1295PubMedCrossRef

Title: Deficiency of Invariant NK T Cells in Crohn's Disease and Ulcerative Colitis
Authors: Randall H. Grose
Fiona M. Thompson
Alan G. Baxter
Daniel G. Pellicci
Adrian G. Cummins
Publication date: 01-06-2007
Publisher: Kluwer Academic Publishers-Plenum Publishers
Published in: Digestive Diseases and Sciences / Issue 6/2007
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-006-9261-7

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Deficiency of Invariant NK T Cells in Crohn's Disease and Ulcerative Colitis

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2007

Liver Fibrosis Is Associated with Decreased Peripheral Platelet Count in Patients with Chronic Hepatitis B and C

Extended Octreotide Suppression Test to Determine Hormone Responsiveness of Multiple Type I Gastric Carcinoid Tumors

Small Early Invasive Colon Cancer Near the Splenic Flexure Successfully Diagnosed by Intraoperative Magnifying Endoscopy

A Fulminant Enterocolitis

Detection and Treatment of Early Flat and Depressed Colorectal Cancer Using High-Magnification Chromoscopic Colonoscopy: A Change in Paradigm for Western Endoscopists?

Pneumocystis jiroveci (carinii) Pneumonia After Infliximab Therapy: A Review of 84 Cases

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page